



Quinolizidine alkaloids from the curare adjuvant *Clathrotropis glaucophylla*

Anne-Lise Sagen, Jürg Gertsch, Rita Becker, Jörg Heilmann, Otto Sticher*

Department of Applied BioSciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zurich,
Winterthurerstr. 190, CH-8057 Zurich, Switzerland

Received 8 July 2002; received in revised form 13 August 2002

Abstract

The bark of *Clathrotropis glaucophylla* (Fabaceae) is used as admixture of curare arrow poison by the Yanomamö Amerindians in Venezuela. A new quinolizidine alkaloid (QA), (–)-13 α -hydroxy-15 α -(1-hydroxyethyl)-anagryne [(–)-clathrotropine], was isolated from the alkaloid extract of *C. glaucophylla* bark, together with eleven known QAs: (–)-anagryne, (–)-thermopsine, (–)-baptifoline, (–)-epibaptifoline, (–)-rhombifoline, (–)-tinctorene, (–)-cytisine, (–)-*N*-methylcytisine, (–)-lupanine, (–)-6 α -hydroxylupanine and (+)-5,6-dehydrolupanine. The isolation and structure elucidation were performed with the aid of chromatographic (TLC, HPLC and CC) and spectroscopic (UV and 1D/2D NMR) methods, and mass spectrometry. To our knowledge, this is the first time quinolizidine alkaloids have been isolated from an arrow poison ingredient. It is also the first report on *Clathrotropis* species being used for preparation of arrow poison.

© 2002 Elsevier Science Ltd. All rights reserved.

Keywords: *Clathrotropis glaucophylla*; Fabaceae; (–)-13 α -Hydroxy-15 α -(1-hydroxyethyl)-anagryne; Quinolizidine alkaloids; Curare

1. Introduction

Clathrotropis is a small genus of the Fabaceae family, tribe Sophoreae, with six species endemic to tropical South America. *C. glaucophylla* Cowan was collected in the rainforests of the upper Orinoco in Venezuela in 1999, during ethnobotanical fieldwork among the Yanomamö Amerindians. Our ethnobotanical investigation has revealed that the species *C. glaucophylla* and *C. macrocarpa* (wapu koki) are of great economic importance to the Yanomamö, the seeds playing a significant role in alimentation, and the bark being used as ingredient of curare arrow poison.

Members of the Sophoreae are known to produce quinolizidine alkaloids, which are the largest single group of legume alkaloids. They appear to be restricted to the more primitive tribes of the Fabaceae, and have thus been shown to be of some use in establishing phylogenetic relationships at the generic and tribal level (Kinghorn and Balandrin, 1984).

To date, only three chemical studies have been carried out on *Clathrotropis* species. One concerning the silica content of *Clathrotropis* wood (Amos, 1951), the two others reporting quinolizidine alkaloids from *C. brachypetala* seeds (Hatfield et al., 1980) and *C. macrocarpa* leaves (Ricker et al., 1994), respectively. In the present paper we report on the isolation and structural elucidation of a new QA, (–)-13 α -hydroxy-15 α -(1-hydroxyethyl)-anagryne (**1**). The ¹³C NMR spectral data (in MeOD) for the known compounds (–)-anagryne (**2**), (–)-thermopsine (**3**), (–)-baptifoline (**4**), (–)-epibaptifoline (**5**), (–)-rhombifoline (**6**), (–)-tinctorene (**7**), (–)-cytisine (**8**), (–)-*N*-methylcytisine (**9**), (–)-lupanine (**10**), (–)-6 α -hydroxylupanine (**11**) and (+)-5,6-dehydrolupanine (**12**) are reported for the first time (Table 1).

2. Results and discussion

Open column chromatography (CC) and preparative HPLC of the alkaloid extract obtained from the bark of *C. glaucophylla*, yielded 12 alkaloids, of which one was new to the literature.

* Corresponding author. Tel.: +41-1-635-6050; fax: +41-1-635-6882.

E-mail address: otto.sticher@pharma.anbi.ethz.ch (O. Sticher).

with H-15 in the COSY spectrum and with C-14 in the HMBC spectrum. This information confirmed the substitution of a 1-hydroxyethyl group at C-15. The configuration of compound **1** was determined to be relative 7*R*, 9*R*, 11*R*, 13*S*, 15*S* after observation of cross peaks between H-11, H-13 and H-15, between H-11 and H-10 α / β , and between H-17 α , H-8 β , H-12 α and H-14 α in the ROESY spectrum. Hence, the substance was identified as (–)-13 α -hydroxy-15 α -(1-hydroxyethyl)-anagryne, and was given the trivial name (–)-clathrotropine.

It is known that QAs have toxicological and pharmacological activities. They interact with ACh receptors as agonists and some inhibit Na⁺ and K⁺ channels, which might lead to respiratory paralysis and ventricular arrest at high doses (Kinghorn and Balandrin, 1984; Wink, 1998). This suggests that *C. glaucophylla* might be an active ingredient in curare, and therefore confirms the indigenous use of this admixture.

3. Experimental

3.1. General experimental procedures

CC: silica gel 60, 40–63 and 63–200 μ m (Merck); aluminium oxide 60 type 507C neutral, activity III 50–150 μ m (Fluka). HPLC: Merck-Hitachi L-7150 pump connected to a Merck-Hitachi L-7200 Injector, a Merck-Hitachi L-7400 UV detector, and a Knauer HPLC column (LiChrosorb Si60, 5 μ m; 250 \times 16 mm); Merck-Hitachi L-6200 pump connected to a Rheodyne 7125 Injector, a Merck-Hitachi L-4000 UV detector, a Merck D-2500 Chromato-integrator, and a Knauer HPLC column (LiChrosorb Si60, 5 μ m; 250 \times 8 mm). TLC: Silica gel 60 F_{254} precoated aluminium plates (0.2 mm, Merck); aluminium oxide 60 F_{254} aluminium sheets (Merck). Detection: Dragendorff's reagent. Optical rotation: Perkin-Elmer 241 polarimeter. UV: Uvikon 930 spectrophotometer, HR-MALDI-MS: Ionspec Ultima FTMS spectrometer with 2,5-dihydroxybenzoic acid (DHB) as matrix. DEI-MS: micromass Tribrid double focusing mass spectrometer at 70 eV. ¹³C NMR, DEPT-135, DEPT-90 for all compounds and ¹H, [¹H,¹H] COSY, [¹³C,¹H] HSQC, [¹³C,¹H] HMBC and [¹H,¹H] ROESY for compounds **6**, **9** and **11** were measured on Bruker AMX-300 at 295 K (operating at 300.13 MHz for ¹H, and 75.47 MHz for ¹³C), ¹H, [¹H,¹H]-COSY, [¹³C,¹H]-HSQC, [¹³C,¹H]-HSQC-TOCSY, [¹³C,¹H]-HMBC and [¹H,¹H]-ROESY experiments for all the other compounds were measured on a Bruker DRX-500 at 295 K (operating at 500.13 MHz for ¹H, and 125.77 MHz for ¹³C), chemical shifts δ were given in ppm and coupling constants *J* in Hz. The spectra were measured in CD₃OD for all the compounds and also in CDCl₃ for compound **2**, **5**, **6**, **8**, **9**,

10, **11** and **12** to compare with the literature. The spectra were referenced against residual non-deuterated solvent.

3.2. Plant material

The bark of *C. glaucophylla* Cowan was collected in Venezuela in 1999, in the surroundings of the Yanomamĩ village Hasupĩweitheri (primary forest). An herbarium sample (JG-134) exists in VEN (Herbario Nacional de Venezuela) and in MYF (Herbario Ovalles, Universidad Central de Venezuela). The plant material was collected during an ethnobotanical project based on an international contract (Contrato de Acceso a los Recursos Fitogenéticos) between the Ministry of Environment of Venezuela (MARNR) and Swiss Federal Institute of Technology (No. 2–1-99), according to the Andean Pact Decision 391. Prior informed consent from the Yanomamĩ and permits from INPARQUES, D.A.I., as well as ORPIA and the Guardia Nacional were obtained in 1999.

3.3. Extraction and isolation

Air-dried and ground material (250 g) was macerated to exhaustion at room temperature with EtOH 75%. The concentrated EtOH extract (32.7 g) was suspended in HCl (0.1 N) and extracted with CH₂Cl₂ (three times). The acidic solution was brought to pH 9 with 25% NH₄OH and extracted with CH₂Cl₂ (four times). The remaining water extract was brought to pH 11 with 25% NH₄OH and again extracted with CH₂Cl₂ (four times). The two CH₂Cl₂ extracts were combined and evaporated to dryness, yielding a dark brown syrup (alkaloid extract *1*: 750 mg). For primary fractionation the alkaloid extract *1* (730 mg) was submitted to open column (CC) on silica gel, using mixtures of dichloromethane and methanol of increasing polarity as mobile phase. This gave fractions 1–14. Compounds **2** (3 mg) and **10** (9 mg) were isolated from fraction 8 and 10, respectively, using CC with aluminium oxide as stationary phase and hexane–ethyl acetate–ethanol of increasing polarity as mobile phase.

Air-dried and ground material (750 g) was successively macerated to exhaustion with CH₂Cl₂, MeOH and MeOH–H₂O (80:20) at room temperature. The MeOH extract (71.1 g) and the MeOH–H₂O extract (11.4 g) were subsequently subjected to an alkaloid extraction as described above. The resulting alkaloid extract was added to the remaining fractions of alkaloid extract *1* to give alkaloid extract *2* (1.5 g).

Alkaloid extract *2* was submitted to CC on silica gel, using CH₂Cl₂–MeOH–25% NH₄OH¹ of increasing polarity as mobile phase. Eight fractions were obtained,

¹ 1.2 ml NH₃/500 ml CH₂Cl₂–MeOH.

of which one was pure **2** (16 mg). Compounds **6** (9 mg), **7** (1.2 mg) and **3** (3 mg) were isolated by normal phase HPLC from fractions 2, 3, and 4, respectively. The mobile phase was CH₂Cl₂–MeOH–25% NH₄OH¹ (97:3). Fractions 6 and 7 were further fractionated using the same stationary and mobile phases as the primary fractionation. Purification of fractions 6.2, 6.3, 6.7 and 7.2 by normal phase HPLC, using CH₂Cl₂–MeOH–25% NH₄OH¹ (96:4) as mobile phases, resulted in the isolation of compounds **1** (9 mg), **2** (20 mg), **4** (3.5 mg), **5** (9 mg), **8** (7.5 mg), **9** (15 mg) and **12** (18 mg). Compound **11** (8 mg) was obtained from fraction 6.5 after an open column with aluminium oxide as stationary phase and hexane–ethyl acetate–ethanol of increasing polarity as mobile phase.

3.4. (–)-Clathrotropine (**1**)

$[\alpha]_D^{23}$ –146 (EtOH, *c* 0.1). UV $\lambda_{\max}^{\text{MeOH}}$ nm (log ϵ): 205 (2.67), 234 (2.79), 309 (2.87). HR-MALDI-MS (pos. mode): 305.1845 [M+H]⁺ (calculated for C₁₇H₂₄N₂O₃, 305.1865). DEI-MS *m/z* (rel. int.): 302 (21), 286 (39), 268 (24), 259 (62), 245 (100), 215 (23), 160 (21), 146 (28), 44 (44). ¹³C NMR in Table 1. ¹H NMR (MeOD, 500.1 MHz) δ 7.47 (1H, *dd*, *J*=7.0, 8.9, H-4), δ 6.41 (1H, *dd*, *J*=1.3, 9.0 Hz, H-3), δ 6.30 (1H, *dd*, *J*=1.2, 7.0, H-5), δ 4.13 (1H, *d*, *J*=15.4, H-10 α), δ 3.92 (1H, *dd*, *J*=6.3, 15.4, H-10 β), δ 3.75 (1H, *m*, H-13), δ 3.57 (1H, *m*, H-18), δ 3.12 (1H, *bs*, H-7), δ 3.06 (1H, *dd*, *J*=2.0, 11.2, H-17 α), δ 2.96 (1H, *bd*, *J*=12.5, H-11), δ 2.74 (1H, *dd*, *J*=2.1, 11.4, H-17 β), δ 2.36 (1H, *ddd*, *J*=2.1, 8.5, 12.3, H-15), δ 2.29 (1H, *m*, H-9), δ 2.15 (1H, *bd*, *J*=13.2, H-8 β), δ 1.94 (1H, *m* (*pseudo q*), *J*=12.5, H-12 α), δ 1.85 (1H, *bd*, *J*=13.2, H-8 α), δ 1.58 (1H, *m*^{*}, H-14 β), δ 1.56 (1H, *m*^{*}, H-12 β), δ 1.36 (1H, *m* (*pseudo q*), *J*=12.5, H-14 α), δ 0.99 (3H, *d*, *J*=6.2, H-19). *overlap.

3.5. (–)-Tinctorine (**7**)

$[\alpha]_D^{23}$ –59 (EtOH, *c* 0.1). ¹³C NMR in Table 1. ¹H NMR (MeOD, 500.1 MHz) δ 7.46 (1H, *dd*, *J*=7.0, 8.9, H-4), δ 6.41 (1H, *dd*, *J*=1.3, 8.9, H-3), δ 6.26 (1H, *dd*, *J*=1.1, 7.0, H-5), δ 5.81 (1H, *m*, H-15), δ 5.14 (1H, *m*, *J*=17.0, H-16a), δ 5.08 (1H, *td*, *J*=1.3, 10.1, H-16b), δ 3.93 (2H, *m*^{*}, H-10 α , H-10 β), δ 3.02 (1H, *bd*, *J*=2.2, H-7), δ 2.91 (2H, *m*^{*}, H-11, H-13a), δ 2.51 (1H, *m*, *J*=11.4, H-13b), δ 2.45 (2H, *m*^{*}, H-9, H-14a), δ 2.33 (1H, *m*^{*}, H-14b), δ 2.23 (3H, *s*, N-CH₃), δ 2.07 (1H, *td*, *J*=2.8, 13.4, H-8a), δ 1.70 (1H, *brdd*, *J*=1.3, 13.3, H-8b). *overlap.

Acknowledgements

We thank M. Baumgartner for assisting in the isolation of some of the substances and Dr. O. Zerbe and Dr. K. Winkelmann (Institute of Pharmaceutical Sciences, ETH Zurich) for recording NMR spectra. Thanks are also due to Dr. W. Amrein, Mr. R. Häfliger, Mr. O. Greter (Institute of Organic Chemistry, ETH Zurich) for recording mass spectra.

References

- Abdel Halim, O.B., Sekine, T., Saito, K., Halim, A.F., Abdel-Fattah, H., Murakoshi, I., 1992. (+)-12 α -Hydroxylupanine, a lupine alkaloid from *Lygos raetam*. *Phytochemistry* 31, 3251–3253.
- Al-Azizi, M.M., Al-Said, M.S., El-Olemy, M.M., Abdel Sattar, E., Khalifa, A.S., 1994. Rhombifoline and 5,6-dehydrolupanine from *Anagyris foetida* L. *Archives of Pharmacol Research* 17, 393–397.
- Amos, G.L., 1951. Some siliceous timbers of British Guiana. *Caribbean Forester* 12, 133–137.
- Asres, K., Phillipson, J.D., Mascagni, P., 1986. Alkaloids of *Bolusanthus speciosus*. *Phytochemistry* 25, 1449–1452.
- Atta-ur-Rahman, Pervin, A., Choudhary, M.I., 1991. Sophazrine—a novel quinolizidine alkaloid from *Sophora griffithii*. *Journal of Natural Products* 54, 929–935.
- El-Shazly, A., Sarg, T., Ateya, A., Abdel Aziz, E., Witte, L., Wink, M., 1996. Quinolizidine alkaloids from *Argyrobolium uniflorum*. *Pharmazie* 51, 768–772.
- Greinwald, R., Schultze, W., Czygan, F.-C., 1990. Über die Alkaloidzusammensetzung der oberirdischen Teile von *Laburnum watereri* (Kirchn.) Dipp. *Biochemie und Physiologie der Pflanzen* 186, 1–10.
- Hatfield, G.M., Keller, W.J., Rankin, J.M., 1980. Quinolizidine alkaloids of *Clathrotropis brachypetala*. *Journal of Natural Products* 43, 164–167.
- Kennelly, E.J., Flynn, T.J., Mazzola, E.P., Roach, J.A., McCloud, T.G., Danford, D.E., Betz, J.M., 1999. Detecting potential teratogenic alkaloids from blue cohosh rhizomes using an in vitro rat embryo culture. *Journal of Natural Products* 62, 1385–1389.
- Kinghorn, D.A., Balandrin, M.F., 1984. Quinolizidine alkaloids of the Leguminosae: structural types, analysis, chemotaxonomy, and biological activities. In: Pelletier, W.S. (Ed.), *Alkaloids: Chemical and Biological Perspectives*, 2. John Wiley & Sons, New York, pp. 105–148.
- Mikhova, B., Duddeck, H., 1998. ¹³C NMR spectroscopy of tri- and tetracyclic quinolizidine alkaloids compilation and discussion. *Magnetic Resonance in Chemistry* 36, 779–796.
- Ricker, M., Veen, G., Daly, D.C., Witte, L., Sinta, V.M., Chota, I.J., Czygan, F.C., 1994. Alkaloid diversity in eleven species of *Ormosia* and in *Clathrotropis macrocarpa* (Leguminosae-Papilionoideae). *Brittonia* 46, 355–371.
- Saito, K., Murakoshi, I., 1995. Chemistry, biochemistry and chemotaxonomy of lupine alkaloids in the Leguminosae. In: Atta-ur-Rahman (Ed.), *Studies in Natural Products Chemistry*, 15. Elsevier Science, Amsterdam, pp. 519–549.
- Wang, Y.-H., Li, J.-S., Jiang, Z.-R., Kubo, H., Higashiyama, K., Ohmiya, S., 2000. Lupine alkaloids from Chinese *Maackia amurensis*. *Chemical and Pharmaceutical Bulletin* 48, 641–645.
- Wink, M., 1998. Modes of action of alkaloids. In: Roberts, M.F., Wink, M. (Eds.), *Alkaloids: Biochemistry, Ecology, and Medicinal Applications*. Plenum Press, New York, pp. 301–326.